Working… Menu

Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04596839
Recruitment Status : Active, not recruiting
First Posted : October 22, 2020
Last Update Posted : June 1, 2021
Information provided by (Responsible Party):
Dr. Md. Alimur Reza, Beximco Pharmaceuticals Ltd.

Brief Summary:

Background - A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness COVID-19 in Wuhan City, China. WHO declared a public health emergency outbreak of this virus on 30 January 2020 and declared COVID-19 a global pandemic on 11 March, 2020. Bangladesh reported its first case on March 8, 2020 and first fatality on April 1, 2020. Bangladesh had shown a staggered course of COVID-19 transmission initially but a surge in cases was observed from April, 2020.

Remdesivir remains as the only potential therapy for the treatment of COVID-19 till date. Based on several pre-clinical studies in SARS-CoV and MERS-CoV infections, Animal trials in COVID-19 and data from human trials, this randomized, controlled, open label trial will evaluate the antiviral activity and safety of Remdesivir in Bangladeshi hospitalized patients with severe COVID-19.

This study finding will provide knowledge if Remdesivir is effective enough to treat Bangladeshi COVID-19 hospitalized patients with adequate safety and tolerability. The result of this study will help the key opinion leaders regarding the matter, to take appropriate decision regarding usage of Remdesivir for the treatment of COVID-19 in Bangladesh.

Study Procedure - All patients will receive the standard medical care for COVID-19+ve at the respective hospitals. Vital signs will be recorded every 24 hrs for 1st 5 days then once in 2 days till discharge or as per the discretion of the attending physicians. After screening the COVID-19 confirmed patients will be randomized into 2 treatment arms.

Patient's safety assessment e. g. blood parameters (CBC, Creatinine, SGPT, RBS, Creatinine, Creatinine Clearance) will be done on screening, day 5 and day 14 or discharge; Chest X-ray and ECG on screening and day 14 or discharge. SARS-CoV-2 (viral load) will be looked in on day 5, day 10 and day 14 or at the time of discharge. In case any study patient deteriorates during the study period will be managed as per the guideline of that particular hospital and if needed will be shifted to ICU. Patients who will recover will be discharged as per the national guideline for the COVID-19 hospitalized patients. Patients will be contacted at 28 days either over phone or in person to get their health status since discharge.

Condition or disease Intervention/treatment Phase
Covid19 Drug: Remdesivir Other: Standard of Care Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial
Actual Study Start Date : September 4, 2020
Actual Primary Completion Date : April 30, 2021
Estimated Study Completion Date : July 31, 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Remdesivir with Standard of Care Treatment for COVID-19 Infection
Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
Drug: Remdesivir
Remdesivir INN 100 mg lyophilized powder for infusion

Standard of Care Treatment for COVID-19 Infection
Participants will receive continued standard of care therapy.
Other: Standard of Care
Standard of Care Treatment for COVID-19 Infection

Primary Outcome Measures :
  1. Duration of hospital stay (Days) [ Time Frame: 28 Days ]

Secondary Outcome Measures :
  1. Time to Clinical Improvement (TTCI) [ Time Frame: 28 Days ]

    Time to clinical improvement (censored at Day 28), defined as the time (in days) from randomization of study treatment until a decline of two categories on a six-category ordinal scale of clinical status (1 ꞊ discharged; 6 ꞊ death) or live discharge from hospital.

    Six-category ordinal scale:

    1. Hospital discharge or meet discharge criteria
    2. Hospitalization, not requiring supplemental oxygen;
    3. Hospitalization, requiring supplemental oxygen (but not NIV/ HFNC);
    4. ICU/hospitalization, requiring NIV/ HFNC therapy;
    5. ICU, requiring ECMO and/or IMV;
    6. Death;

  2. All causes mortality [ Time Frame: 28 Days ]
  3. Duration (days) of mechanical ventilation [ Time Frame: 28 Days ]
  4. Duration (days) of supplemental oxygenation [ Time Frame: 28 Days ]
  5. Time to 2019-nCoV RT-PCR negativity in Nasopharyngeal Swab [ Time Frame: 28 Days ]
  6. Frequency of serious adverse drug events [ Time Frame: 28 Days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥18 years at time of signing Informed Consent Form
  2. Hospitalized with diagnosed COVID-19 confirmed by RT-PCR test ≤ 7 days before randomization with any one following criteria

    • Respiratory distress (≥30 breaths/min);
    • Finger oxygen saturation ≤93% at rest;
    • Arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤300mmHg
  3. Willingness of study participant to accept randomization to any assigned treatment arm
  4. Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study

Exclusion Criteria:

  • Physician makes a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely.
  • Severe liver disease (Alanine Transaminase (ALT) or Aspartate Transaminase (AST) > 5 times the upper limit of normal)
  • Estimated glomerular filtration rate (eGFR) < 30 ml/min (including patients receiving hemodialysis or hemofiltration).
  • Mechanically ventilated (including V-V ECMO) ≥ 5 days, or any duration of V-A ECMO.
  • Known hypersensitivity to the Remdesivir, the metabolites, or formulation excipient
  • Pregnancy or breast feeding.
  • Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04596839

Layout table for location information
Combined Military Hospital
Dhaka, Bangladesh, 1206
Sponsors and Collaborators
Dr. Md. Alimur Reza
Layout table for investigator information
Principal Investigator: Major General Md. Azizul Islam, MBBS, FCPS Combined Military Hospital
Additional Information:

Layout table for additonal information
Responsible Party: Dr. Md. Alimur Reza, Manager, Medical Affairs, Beximco Pharmaceuticals Ltd. Identifier: NCT04596839    
Other Study ID Numbers: BEX-06001
First Posted: October 22, 2020    Key Record Dates
Last Update Posted: June 1, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dr. Md. Alimur Reza, Beximco Pharmaceuticals Ltd.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases